Actin bundling protein fascin expression in ovarian neoplasms: Comparison of histopathologic features of tumors obtained by the first and secondary cytoreduction surgeries

Purpose of investigation: The aim of the study was to compare the fascin expression pattern and histopathologic features of malign epithelial ovarian tumors obtained by the primary and secondary surgeries.

Methods: The samples of 94 epithelial ovarian carcinomas, 35 secondary surgeries for ovarian carcinomas, 13 borderline epithelial ovarian tumors, 25 cystadenomas and four normal ovarian tissues were stained by means of fascin immunohistochemistry. Secondary surgeries included in the study were secondary cytoreduction at the time of second-look laparotomy (SLL), interval debulking surgery after neoadjuvant chemotherapy or secondary cytoreductive surgery in patients with recurrent epithelial ovarian carcinoma.

Results: Mean rank value of the stromal fascin score was higher in 94 cases of malign epithelial ovarian carcinomas than borderline epithelial tumors, cystadenomas and normal ovaries (.000, p < 0.001). There was no significant difference in terms of total epithelial fascin score (.685, p > 0.05) and total stromal fascin score (.572, p > 0.05) between the primary and the secondary surgeries of epithelial ovarian carcinomas.

Conclusions: Regarding the results of stromal fascin expression in 94 epithelial ovarian carcinomas, we hypothesized that cell-matrix interaction was an important step in the progression of malign epithelial ovarian neoplasms. Our study showed that the initial tumorigenic phenotype did not change with time and use of cisplatinum-based combination chemotherapy. Further studies with close follow-up of patients are necessary to reveal the role of fascin on matrix degradation mechanisms which might be the cause of the recurrences in ovarian neoplasms.

Epithelial ovarian carcinoma; Fascin immunohistochemistry; Second-look laparotomy; Tumorigenic phenotype

[1] Karlan B.Y, Cass I.: "Neoplasms of the ovarian and fallopian tube". In: Scott J.R., Gibbs R.S., Karlan B.Y, Haney A.F. (eds.), Danforth's Obstetrics and Gynecology. 9,h edition, Philadelphia Lippincott Williams & Wilkins, 2003, 971.

[2] Rahaman J., Dottino P., Jennings T.S., Holland J., Cohen CJ "The second-look operation improves survival in suboptimally de bulked Stage III ovarian cancer patients". Int. J. Gynecol Cancer, 2005, 15, 19.

[3] Chi D.S., Franklin C.C., Levine D.A. et al.: "Improved optimal cytoreduction rates for Stages IIIC and IV epithelial ovarian, fallopian tube, primary peritoneal cancer: a change in surgical approach". Gynecol. Oneal., 2004, 94, 650.

[4] Leitao M.M., Boyd J., Hummer A. et al.: "Clinicopathologic analysis of early-stage sporadic ovarian carcinoma". Am. J. Surg. Pathol., 2004, 28, 147.

[5] Leber T.M., Balkwill ER.: "Regulation of monocyte MMP-9 production by T NF-alpha and tumour derived soluble factor (MMPSF)". Br. J. Cancer, 1998, 78, 724.

[6] Davidson B., Goldberg L, Berner A., Kristensen G.B., Reich R.: "EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma". Clin. Exp. Metast., 2003, 20, 161.

[7] Ozalp S., Tanu H.M., Yalcin O.T., Kabukcuoglu S., Oner U., Uray M.: "Prognostic value of matrix metalloproteinase-9 (gelatinaseB) expression in epithelial ovarian tumors". Eur. J. Gynaecol. Oneal., 2003, 24, 417.

[8] Adams J.C., Clelland J.D., Collet G.D.M., Matsumura F., Yamashiro S., Zhang L: "Cell-matrix adhesions differentially regulate fascin phosphorylation". Mo!. Biol. Cell, 1999, 10, 4177.

[9] Cohan C.S., Welnhofer E.A., Zhao L, Matsumura F, Yamashiro S.: "Role of the actin bundling protein fascin in growth cone morphogenesis: localization in filopodia and lamellipodia". Cell Motil. Cytoskeleton, 2001, 48, 109.

[10] Duh FM., Latif F, Weng Y et al.: "cDNA cloning and expression of the human homolog of the sea urchin fascin and Drosophila signed genes which actin-bundling protein". DNA Cell Biol., 1994, 13, 821.

[11] Ishikawa R., Yamashiro S., Kohama K., Matsumura F: "Regulation of actin binding and actin bundling activities of fascin by caldesmon coupled with tropomyosin". J. Biol. Chem., 1998, 273, 26991.

[12] Hu W., McCrea P.D., Deavers M., Kavanagh J.J., Kudelka A.P., Verschraegen C.F: "Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors". Clin. Exp. Metastasis, 2000, 18, 83.

[13] Grothey A., Hashizume R., Ji H. et al.: "C-erbB-2/Her-2 upregulates fascin, an actin-bundling protein associated with cell motility, in human breast cancer cell lines". Oncogene, 2000, 19, 4864.

[14] Guvakova M.A., Boettiger D., Adams J.C.: "Induction of fascin spikes in breast cancer cells by activation of the insulin-like growth factor-I receptor". Int. J. Biochem. Cell Biol., 2002, 34, 685.

[15] Kempf W., Levi E., Kamarashev J. et al.: "Fascin expression in CD30-positive cutaneous lymphoproliferative disorders". J. Cutan. Pathol., 2002, 29, 295.

[16] Fan G., Kotylo P., Neiman R.S., Braziel R.M. et al.: "Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease". Am. J. Clin. Pathol., 2003, 119, 199.

[17] Maitra A., Iacobuzio-Donahue C., Rahman A. et al.: "Immunoh1stochemical validation of a novel epithelial and a novel stroma marker of pancreatic ductal adenocarcinoma identified by global express microarrays: sea urchin fascin homolog and heat shock protein 47". Am. J. Clin. Pathol., 2002, 118, 52.

[18] Pelosi G., Pastorino U., Pasini F et al.: "Independent prognostic value of fascin immunoreactivity in Stage I non small cell lung cancer". Br. J. Cancer, 2003, 88, 537.

[19] Pelosi G., Barisella M., Pasini F. et al.: "CD! 17 immunoreactivity in Stage I adenocarcinoma and squamous cell carcinoma of the lung: relevance to prognosis in a subset of adenocarcinoma patients". Mod. Pathol., 2004, 17, 711.

[20] Pelosi G., Pasini F., Sonzogni A. et al.: "Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I non small cell lung carcinoma". Cancer, 2003, 97, 2487.

[21] Rong J., Xu L.Y., Cai W.J. et al.: "Expression of fascin 1 gene in the process of the immortalized esophageal carcinoma carcinogenesis". Ai. Zheng., 2004, 23, 243.

[22] Hashimoto Y., Shimada Y., Kawamura J., Yamasaki S., Imamura M.: "The prognostic relevence of fascin expression in human gastric carcinoma". Oncology, 2004, 67, 262.

[23] Jawhari A.U., Buda A., Jenkins M. et al.: "Fascin, an actin bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro". Am. J. Pathol., 2003, 162, 69.

[24] Goncharuk V.N., Ross J.S., Carlson J.A.: "Actin-binding protein fascin expression in skin neoplazi". J. Cutan. Pathol., 2002, 29, 430.

[25] Wong V., Ching D., McCrea P.D., Firestone G.L.: "Glucocorticoid down-regulation of fascin protein expression is required for steroid-induced formation of tight junctions and cell-cell interactions in rat mammary epithelial tumor cells". J. Biol. Chem., 1999, 274, 5443.

[26] Guan Y., Woo P.L., Rubenstein N.M., Firestone G.L.: "Transforming growth factor-a abrogates the glucocorticoid stimulation of tight junction formation and reverses the steroid-induced downregulation of fascin in rat mammary epithelial tumor cells by a Ras-depentent pathway". Exp. Cell Res., 2002, 273, 1.

[27] Shonukan O.T., Bagayogo I., McCrea P.D., Chao M., Hempstead B.: "Neurotropin-induced melanoma cell migration is mediated through actin-bundling protein fascin". Oncogene, 2003, 22, 3616.

[28] MiH!er M., Kramer P.H.: "Integrated cell function: apoptosis". In: Arias I.M., Boyer J.L., Chisari F.V., Fausto N., Schachter D., Shafritz D. (eds.), The Liver Biology and Pathobiology. 4'" edition, Philadelphia, Lippincott Williams &Wilkins, 2001, 187.

[29] Schneiderman D., Kim J.M., Senterman M., Tsang B.K.: "Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells". Apoptosis, 1999, 4, 271.

[30] Abuharbeid S., Apel J., Zugmaier G. et al.: "Inhibition of Her-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells". Naunyn-Schmiedeberg's Arch. Pharmacol., 2005, 371, 141.

[31] Loizzi V., Chan J.K., Osann K., Cappuccini F., DiSaia P.J., Berman M.L.: "Survival outcomes in patients with reccurent ovarian cancer who were treated with chemoresistance assayguided chemotherapy". Am. J. Obstet. Gynecol., 2003, 189, 1301.

[32] Eltabbakh G.H., Mount S.L., Beatty B., Simmons-Arnold L., Cooper K., Morgan A.: "Factors associated with cytoreducibility among women with ovarian carcinoma". Gynecol. Oncol., 2004, 95, 377.

[33] Goff B.A., Paley P.J., Greer B.E., Gown A.M.: "Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma". Gynecol. Oncol., 2001, 81, 18.

[34] Ozalp S.S., Yals;m 0.T., Ba􀃿aran N., Artan S., Kabukcuoglu S., Minsin T.H.: "Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer". Eur. J. Gynaec. Oncol., 2000, 21, 282.

[35] Ozalp S.S., Yals;m O.T., Tamr M., Kabukcuoglu S., Etiz E.: "Muitidrug resistance gene-I (PgP) expression in epithelial ovarian malignancies". Eur. J. Gynaecol. Oncol., 2002, 23, 337.